Aisling Capital is the famous VC, which was founded in 2000. The fund was located in North America if to be more exact in United States. The main department of described VC is located in the New York.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Aisling Capital, startups are often financed by Vivo Capital, New Enterprise Associates, Sofinnova Investments. The meaningful sponsors for the fund in investment in the same round are Vivo Capital, New Enterprise Associates, Venrock. In the next rounds fund is usually obtained by OrbiMed, Kearny Venture Partners, Polaris Partners.
The top amount of exits for fund were in 2014. The top activity for fund was in 2013. Despite it in 2019 the fund had an activity. The average startup value when the investment from Aisling Capital is 100-500 millions dollars. Considering the real fund results, this VC is 0 percentage points less often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in 2-6 deals every year. Comparing to the other companies, this Aisling Capital performs on 12 percentage points more the average number of lead investments.
The fund has exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Loxo Oncology, Zeltiq Aesthetics, BridgeBio We can highlight the next thriving fund investment areas, such as Therapeutics, Medical.
We also calculated 7 valuable employees in our database.
Related Funds
Funds with similar focus
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Bicara Therapeutics | $165M | 12 Dec 2023 | Cambridge, Massachusetts, United States | ||
Garuda Therapeutics | $62M | 07 Feb 2023 | Natick, Massachusetts, United States | ||
Forge Biologics | $90M | 12 Sep 2022 | Ohio, United States | ||
Dren Bio | $65M | 14 Jun 2022 | California, United States | ||
Garuda Therapeutics | $72M | 23 Sep 2021 | Natick, Massachusetts, United States | ||
Antios Therapeutics | $96M | 12 Apr 2021 | Atlanta, Georgia, United States | ||
| $95M | 12 Mar 2021 | Basel, Basel-City, Switzerland | |||
Biomea Fusion | $56M | 06 Jan 2021 | Redwood City, California, United States | ||
Reneo Pharmaceuticals | $95M | 09 Dec 2020 | San Diego, California, United States |
– Garuda Therapeutics from Cambridge develops off-the-shelf, durable blood stem cell therapies.
– Series A funding of $72m brings company valuation to more than $1b.
– The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others.
– Wugen, Inc. completed an oversubscribed $172m Series B financing led by Abingworth and Tybourne Capital Management, and joined by new investors Fidelity Management and Research Company, Intermediate Capital Group, Sands Capital, Aisling Capital Management, Alexandria Venture Investments, Velosity Capital and Falcon Edge Capital.
– Existing investors, including RiverVest Venture Partners, LYZZ Capital, and Lightchain Capital, also participated.
– In connection with the financing, Bali Muralidhar, M.D., Ph.D., Managing Partner at Abingworth, Bosun Hau, Managing Director at Tybourne Capital Management, and Peter Kiener, Ph.D., Venture Partner at ICG, will join Wugen’s Board of Directors.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Bicara Therapeutics | $165M | 12 Dec 2023 | Cambridge, Massachusetts, United States | ||
Garuda Therapeutics | $62M | 07 Feb 2023 | Natick, Massachusetts, United States | ||
Forge Biologics | $90M | 12 Sep 2022 | Ohio, United States | ||
Dren Bio | $65M | 14 Jun 2022 | California, United States | ||
Garuda Therapeutics | $72M | 23 Sep 2021 | Natick, Massachusetts, United States | ||
Antios Therapeutics | $96M | 12 Apr 2021 | Atlanta, Georgia, United States | ||
| $95M | 12 Mar 2021 | Basel, Basel-City, Switzerland | |||
Biomea Fusion | $56M | 06 Jan 2021 | Redwood City, California, United States | ||
Reneo Pharmaceuticals | $95M | 09 Dec 2020 | San Diego, California, United States |
